APA (7th ed.) Citation

Morris, J. A., Hanson, J. E., Steffen, B. J., Chu, A. H., Chi-Burris, K. S., Gotz, V. P., & Gordon, R. D. (2005). Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clinical Transplantation, 19(3), 340. https://doi.org/10.1111/j.1399-0012.2005.00344.x

Chicago Style (17th ed.) Citation

Morris, J. A., J. E. Hanson, B. J. Steffen, A. H. Chu, K. S. Chi-Burris, V. P. Gotz, and R. D. Gordon. "Daclizumab Is Associated with Decreased Rejection and Improved Patient Survival in Renal Transplant Recipients." Clinical Transplantation 19, no. 3 (2005): 340. https://doi.org/10.1111/j.1399-0012.2005.00344.x.

MLA (9th ed.) Citation

Morris, J. A., et al. "Daclizumab Is Associated with Decreased Rejection and Improved Patient Survival in Renal Transplant Recipients." Clinical Transplantation, vol. 19, no. 3, 2005, p. 340, https://doi.org/10.1111/j.1399-0012.2005.00344.x.